BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9479873)

  • 21. Design and rationale for novel antifolates.
    Bertino JR; Sobrero A; Mini E; Moroson BA; Cashmore A
    NCI Monogr; 1987; (5):87-91. PubMed ID: 3431593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization by flow cytometry and fluorescein-methotrexate labeling of hydrophilic and lipophilic antifolate resistance in cultured mammalian cells.
    Assaraf YG
    Anticancer Drugs; 1993 Oct; 4(5):535-44. PubMed ID: 8292810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
    Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
    Kobayashi H; Takemura Y; Miyachi H
    Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.
    Rots MG; Pieters R; Peters GJ; van Zantwijk CH; Mauritz R; Noordhuis P; Willey JC; Hählen K; Creutzig U; Janka-Schaub G; Kaspers GJ; Veerman AJ; Jansen G
    Blood; 1999 Nov; 94(9):3121-8. PubMed ID: 10556198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel antifolate drugs.
    Purcell WT; Ettinger DS
    Curr Oncol Rep; 2003 Mar; 5(2):114-25. PubMed ID: 12583828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classical and nonclassical furo[2,3-d]pyrimidines as novel antifolates: synthesis and biological activities.
    Gangjee A; Devraj R; McGuire JJ; Kisliuk RL; Queener SF; Barrows LR
    J Med Chem; 1994 Apr; 37(8):1169-76. PubMed ID: 8164259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.
    Rothem L; Ifergan I; Kaufman Y; Priest DG; Jansen G; Assaraf YG
    Biochem J; 2002 Nov; 367(Pt 3):741-50. PubMed ID: 12139489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
    Zhao R; Babani S; Gao F; Liu L; Goldman ID
    Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
    Assaraf YG
    Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological and biochemical properties of new anticancer folate antagonists.
    Fry DW; Jackson RC
    Cancer Metastasis Rev; 1987; 5(3):251-70. PubMed ID: 3549036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH; Angeles SM; McGuire JJ
    Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
    Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
    J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.
    Fotoohi AK; Albertioni F
    Leuk Lymphoma; 2008 Mar; 49(3):410-26. PubMed ID: 18297517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme studies of methotrexate-resistant human leukemic cell (K562) subclones.
    Koizumi S; Allegra CJ
    Leuk Res; 1992; 16(6-7):565-9. PubMed ID: 1378915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.